2- (4- (quinolin- 2- yl- methoxy)phenyl)- 2- cyclopentylacetic acid

inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source;

Also Known As:

Networked: 12 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Chan, Su Jing: 1 article (01/2020)
2.	De Foo, Chuan: 1 article (01/2020)
3.	Ng, Geelyn J L: 1 article (01/2020)
4.	Ng, Mary P E: 1 article (01/2020)
5.	Seet, Raymond C S: 1 article (01/2020)
6.	Wong, Peter T-H: 1 article (01/2020)
7.	Zhao, Hui: 1 article (01/2020)
8.	Gajda, M: 1 article (09/2007)
9.	Jawień, J: 1 article (09/2007)
10.	Korbut, R: 1 article (09/2007)

Related Diseases

1.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/01/1995 - "Data from the emerging clinical trials with compounds such as zileuton, ICI 204,219, Bay X1005, MK571, MK679, and MK591 are demonstrating the importance of the leukotrienes as mediators of asthma and possibly other diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. "
2.	Respiratory Hypersensitivity 02/01/1996 - "Effect of a novel leukotoriene synthesis inhibitor, BAY x1005, on the antigen-and LPS-induced airway hyperresponsiveness in guinea pigs." 02/01/1996 - "The effects of BAY x1005 on the antigen- and bacterial lipopolysaccharide (LPS)-induced airway hyperresponsiveness in guinea pigs were investigated. " 02/01/1996 - "Simultaneously, BAY x1005 inhibited the antigen-induced airway hyperresponsiveness at doses of 10 and 30 mg/kg and airway eosinophilia (bronchoalveolar lavage study) at a dose of 30 mg/kg. In addition, BAY x1005 at a dose of 30 mg/kg inhibited bacterial LPS-induced airway hyperreactivity to acetylcholine. "
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 02/01/1995 - "Data from the emerging clinical trials with compounds such as zileuton, ICI 204,219, Bay X1005, MK571, MK679, and MK591 are demonstrating the importance of the leukotrienes as mediators of asthma and possibly other diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. "
4.	Eosinophilia 02/01/1996 - "Simultaneously, BAY x1005 inhibited the antigen-induced airway hyperresponsiveness at doses of 10 and 30 mg/kg and airway eosinophilia (bronchoalveolar lavage study) at a dose of 30 mg/kg. In addition, BAY x1005 at a dose of 30 mg/kg inhibited bacterial LPS-induced airway hyperreactivity to acetylcholine. "
5.	Asthma (Bronchial Asthma) 02/01/1995 - "Data from the emerging clinical trials with compounds such as zileuton, ICI 204,219, Bay X1005, MK571, MK679, and MK591 are demonstrating the importance of the leukotrienes as mediators of asthma and possibly other diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. "

Related Drugs and Biologics

1.	Leukotrienes
2.	Antigens
3.	Acetylcholine (Acetylcholine Chloride)
4.	zileuton (Zyflo)
5.	zafirlukast (Accolate)
6.	Arachidonic Acid (Vitamin F)
7.	licofelone
8.	N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamide
9.	5-Lipoxygenase-Activating Proteins
10.	Interleukin-1beta (Interleukin 1 beta)

Related Therapies and Procedures

1.	Investigational Therapies (Experimental Therapy)
2.	Therapeutics
3.	Oral Administration